{"id":239,"date":"2014-09-16T08:15:17","date_gmt":"2014-09-16T08:15:17","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=239"},"modified":"2014-09-16T08:15:17","modified_gmt":"2014-09-16T08:15:17","slug":"nota-informativa-muh-fv-142014","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2014\/09\/16\/nota-informativa-muh-fv-142014\/","title":{"rendered":"Nota Informativa MUH (FV), 14\/2014"},"content":{"rendered":"<p><a style=\"color: #004878;font-family: 'Trebuchet MS', Verdana, Arial, Helvetica, sans-serif\" href=\"http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2014\/NI-MUH_FV_14-2014-agomelatina.htm\">Agomelatina (Thymanax\u00ae, Valdoxan\u00ae) y toxicidad hep\u00e1tica: nuevas recomendaciones de uso<\/a><span style=\"color: #000000;font-family: 'Trebuchet MS', Verdana, Arial, Helvetica, sans-serif;background-color: #ffffff\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Agomelatina (Thymanax\u00ae, Valdoxan\u00ae) y toxicidad hep\u00e1tica: nuevas recomendaciones de uso\u00a0<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-239","post","type-post","status-publish","format-standard","hentry","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=239"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/239\/revisions"}],"predecessor-version":[{"id":240,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/239\/revisions\/240"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}